Study analysis finds Vytorin works better than Lipitor

Share this article:
Merck and Schering-Plough said Monday that new analysis of a previously released study of its jointly marketed Vytorin (ezetimibe/simvastatin) showed it was better at lowering bad cholesterol levels than Pfizer’s top-selling Lipitor (atorvastatin calcium). The study—known as Vytorin Versus Atorvastatin, or Vyva—was presented at the annual scientific meeting of the American College of Cardiology. The new analysis found that a “significantly greater” number of Vytorin users were able to lower their levels of LDL, or “bad cholesterol,” compared with those using Lipitor. Merck and Schering-Plough also said the new analysis showed Vytorin lowered levels of C-reactive protein, or CRP, and apolipoprotein B(1), or Apo B, in a greater percentage of patients than Lipitor. Both CRP and Apo B are believed to be risk markers for cardiovascular disease.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions